Trial Profile
Randomized, Placebo-Controlled, Double-Blind, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-820836 in Healthy Japanese Subjects and Japanese Patients With Depression
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Sep 2018
Price :
$35
*
At a glance
- Drugs Liafensine (Primary)
- Indications Depression
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 16 Apr 2012 Planned end date changed from 1 Apr 2012 to 1 May 2012 as reported by ClinicalTrials.gov.
- 15 Sep 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 30 Aug 2011 Planned initiation date changed from 1 Aug 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.